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LETTER TO THE EDITOR
Does the ob gene product
leptin stimulate erythropoiesis
in patients with chronic renal
failure?
To the Editor: The recently described obese (ob) gene product
leptin, which is exclusively produced in adipocytes and elevated in
obesity, is thought to be a key regulator of food intake [1]. Since
leptin receptors also have been demonstrated in several periph-
eral organs, it appears that the functional role of leptin may also
include other biological functions. Markedly elevated serum lep-
tin levels have recently been demonstrated in patients with
advanced renal failure [2] probably as a result of decreased
catabolism. Renal anemia is primarily due to a decreased ability of
the diseased kidney to synthesize erythropoietin. Treatment with
recombinant human erythropoietin (rhEPO) is effective in virtu-
ally all patients with advanced chronic renal failure (CRF).
However, it is well established that the need for rhEPO varies
substantially between patients with CRF. This has been attributed
to a number of factors such as inflammation, hyperparathyroidism
and iron-deficiency [3]. The potential impact of the body fat mass
and serum leptin levels have not, to the best of our knowledge,
previously been considered. To test the hypothesis whether obe-
sity is associated with less severe anemia in CRF, we have
analyzed the relationship between body mass index and the
degree of anemia in our patients with CRF. In a cohort of 208
unselected predialysis patients studied before rhEPO was avail-
able for clinical use (1978 to 1988), we noted a weak (R 5 0.22),
but significant (P , 0.01), positive relationship between the body
mass index and the hemoglobin level. This finding prompted us to
further investigate the relationships between leptin levels and
rhEPO requirements.
In a cross sectional study, we evaluated body fat mass (DXA),
serum leptin, hemoglobin and the weekly dose of s.c. rhEPO in 58
predialysis (creatinine clearance 9 6 1 ml/min) patients (52 6 2
years) with a body weight of 74 6 2 kg (range 39 to 120 kg). The
average blood hemoglobin level was 99 6 2 g/liter and the average
serum leptin level 25.7 6 5.5 ng/ml. A significantly positive
correlation (R 5 0.34; P , 0.05) between the body fat mass and
hemoglobin and a near-significant correlation (R 5 0.27; P 5
0.055) between log serum leptin and hemoglobin were observed.
Moreover, the weekly rhEPO dose correlated negatively to both
body fat mass (R 5 20.47; P , 0.0002) and the log serum leptin
levels (R 5 20.47; P , 0.0002; Fig. 1).
Our results indicate that the levels of hemoglobin and the
rhEPO requirements are associated to the prevailing amounts of
body fat and the serum leptin levels in patients with CRF. Indeed,
recent results [4–6] suggest that leptin and its receptor B219/OB
constitute a novel hematopoietic pathway that may affect eryth-
ropoiesis particularly in anemic states. The B219 gene product, a
member of the hematopoietin receptor family has been shown to
also be a receptor for leptin, the proliferative effects of which
seem to be at the stem cell level as shown by increased myelopoi-
esis, erythropoiesis and lymphopoiesis [5]. In this context, it is
interesting that the bone marrow contains about 50% adipocytes,
and it has been speculated that the fat cell content of human bone
marrow reflects the requirement for leptin in active hematopoiesis
[5]. Moreover, leptin seems to act synergistically with erythropoi-
etin to increase erythropoiesis [5]. One could therefore speculate
that in clinical states with anemia and insufficient production of
erythropoietin, other hematopoietic factors, such as leptin, will be
increasingly important in stimulating erythropoiesis. It has repeat-
edly been demonstrated that obesity per se is associated with mild
to moderate polycythemia, which has been attributed to hypoxia
caused by obstructive sleep apnoea. Furthermore, since we [2]
recently found unchanged serum leptin levels in patients treated
with hemodialysis as opposed to a marked increase in serum
leptin levels and body fat mass in patients treated with peritoneal
dialysis, it can be speculated that elevated serum leptin levels may
explain, at least partly, why peritoneal dialysis patients usually
have higher hemoglobin levels and require less rhEPO than
hemodialysis patients [3]. However, the putative effect of leptin
on hematopoiesis is probably modest and may act synergistically
with rhEPO under certain conditions. Further prospective and
controlled studies are needed to evaluate whether elevated body fat
mass and serum leptin levels are associated with higher hemoglobin
levels and lower rhEPO requirements in patients with CRF.
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Fig. 1. Relationship (R 5 20.47; P < 0.0002) between serum leptin levels
and the weekly dose of rhEPO in predialysis patients. Note the log scale
on x-axis. Symbols are: (F) males, N 5 37; (h) females, N 5 21.
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